Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder

• Status: Completed
• Trial end date: 2014-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether guanfacine (trade name Intuniv) by itself or in combination with methylphenidate (also known as Ritalin) is helpful for treating hyperactivity in children and adolescents with a Pervasive Developmental Disorders (PDDs).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yale University
• Collaborators: Emory University; Massachusetts General Hospital; National Institute of Mental Health (NIMH); Seattle Children's Hospital; University of California, Los Angeles
• Treatments: Guanfacine

Criteria

Inclusion Criteria:

• Diagnosis of PDD (PDD-NOS, Asperger's Disorder, Autistic Disorder)

• Hyperactivity

• Between ages 5 years 0 months and 13 years 11 months.

• Weight >/= 15 kg (33 lb)

• A mental age of at least 18 months

Exclusion Criteria:

• Prior failed treatment with an adequate trial of guanfacine in the last 2 years

• Concurrent treatment with another psychoactive medication